(Headache[TA])
8,223 results
  • Plasma amylin levels in migraine and after erenumab treatment: A REFORM study. [Journal Article]
    Headache. 2026 Oct 13. [Online ahead of print]Domínguez-Moreno R, Alexander TI, … Ashina HH
  • CONCLUSIONS: Plasma amylin levels did not differ between adults with migraine and HCs, across clinically relevant migraine subgroups, or by response to erenumab. These findings do not support plasma amylin as a clinically useful disease or treatment-response biomarker and are consistent with the broader concept that migraine-relevant peptidergic signaling may be compartmentalized and not captured by peripheral venous blood sampling.
  • Publisher Full Text (DOI)
  • Headache disorders among Indigenous communities: A scoping review undertaken with knowledge keeper guidance. [Review]
    Headache. 2026 Oct 12. [Online ahead of print]Kelly M, Todd CM, … Lena SH
  • CONCLUSIONS: Included studies from Canada, the United States, Australia, and New Zealand reported a high prevalence of headache in some Indigenous communities and suggest that this burden may result from or be associated with a combination of intergenerational trauma, adverse childhood experiences, lower socioeconomic status, head injury, environmental contaminants, and systemic racism resulting in barriers to diagnosis and care. Despite this apparent burden, the literature reveals a paucity of quality, headache-specific research conducted with Indigenous peoples across all four regions of study. To close gaps in headache diagnosis, treatment, and prevention, research and program development must be led by, or conducted in meaningful collaboration with, Indigenous communities in a manner that recognizes and uplifts Indigenous knowledge systems, healing, and conceptualizations of headache.
  • Publisher Full Text (DOI)
  • Headache among patients undergoing cardiac stress testing: Prevalence, clinical characteristics, and identification of myocardial ischemia. [Journal Article]
    Headache. 2026 Oct 08. [Online ahead of print]Prakash S, Mathew C, … Vadodaria VH
  • CONCLUSIONS: Headache occurred in approximately one in 10 patients undergoing TMT, with a similar prevalence among TMT-positive and TMT-negative patients. Cardiac cephalalgia was identified in a small but clinically important subset of patients with myocardial ischemia based on reproduction of headache during stress testing, objective evidence of ischemia, and angiographic confirmation of CAD. Recognition of cardiac cephalalgia is important because treatment of the underlying CAD can substantially improve or resolve headache.
  • Publisher Full Text (DOI)
  • Mitochondrial migraine: A multicenter study based on mitochondrial diseases presenting as encephalopathy and/or myopathy. [Journal Article]
    Headache. 2026 Sep 29. [Online ahead of print]Yan C, Zhang S, … Wu SH
  • CONCLUSIONS: In patients with MD presenting as encephalopathy and/or myopathy, the 1-year frequency of migraine was more than five times higher than that in the general population. Epilepsy and elevated resting blood lactate concentration were identified as factors independently associated with migraine. In patients with MELAS, AHF positivity was associated with distinct and severe migraine phenotypes. Collectively, these findings offer clinical evidence supporting the potential link between migraine and mitochondrial dysfunction.
  • Publisher Full Text (DOI)
  • Orofacial pain disorder or trigeminal autonomic cephalalgia? Insights into pathophysiology and implications in medicine and dentistry. [Review]
    Headache. 2026 Sep 28. [Online ahead of print]Romero-Reyes M, Akerman SH
  • CONCLUSIONS: The potential presence of TACs in the orofacial region can be observed from preclinical models to the clinical setting. The International Classification of Headache Disorders (ICHD) needs to recognize this additional localization, as well as the intraoral one, including dental structures. Education about TACs/TAOPs in the medical and dental setting is vital. Evidence has shown that dentists are one of the first providers that are seen by this patient population due to similarities with dental pain. The dentist specialized in orofacial pain is a key ally in the identification of TACs/TAOPs. The medical/neurology and dental/orofacial pain settings have a great opportunity and responsibility to work together to stop years of pain in this patient population.
  • Publisher Full Text (DOI)